New intraprostatic injectables and prostatic urethral lift for male LUTS

EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction

(2015) Christian Gratzke et al.   EUROPEAN UROLOGY

Obstruction-induced alterations within the urinary bladder and their role in the pathophysiology of lower urinary tract symptomatology.

(2014) Christos Komninos et al.   CUAJ-Canadian Urological Association Journal

Multicentre prospective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

(2013) Anthony L. Cantwell et al.   BJU INTERNATIONAL

Minimally Invasive Prostatic Urethral Lift: Surgical Technique and Multinational Experience

(2013) Thomas A. McNicholas et al.   EUROPEAN UROLOGY

An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders

(2013) Altaf Mangera et al.   EUROPEAN UROLOGY

Treatment of LUTS Secondary to BPH While Preserving Sexual Function: Randomized Controlled Study of Prostatic Urethral Lift

(2013) Kevin T. McVary et al.   Journal of Sexual Medicine

The Prostatic Urethral Lift for the Treatment of Lower Urinary Tract Symptoms Associated with Prostate Enlargement Due to Benign Prostatic Hyperplasia: The L.I.F.T. Study

(2013) Claus G. Roehrborn et al.   JOURNAL OF UROLOGY

Treatment of lower urinary tract symptoms: Agents for intraprostatic injection

(2013) Karl-Erik Andersson   Scandinavian Journal of Urology

Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study

(2012) Emilio Sacco et al.   BJU INTERNATIONAL

A Randomized Double-blind Placebo-controlled Phase 2 Dose-ranging Study of OnabotulinumtoxinA in Men with Benign Prostatic Hyperplasia

(2012) Michael Marberger et al.   EUROPEAN UROLOGY

Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia

(2012) Mostafa M. Elhilali et al.   JOURNAL OF UROLOGY

Urodynamic Effects of Transrectal Intraprostatic Ona botulinum Toxin A Injections for Symptomatic Benign Prostatic Hyperplasia

(2012) Laetitia M.O. de Kort et al.   UROLOGY

Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates

(2012) Ali Hamidi Madani et al.   WORLD JOURNAL OF UROLOGY

Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)

(2011) Henry H. Woo et al.   BJU INTERNATIONAL

Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA)

(2011) Altaf Mangera et al.   EUROPEAN UROLOGY

Preservation of Sexual Function with the Prostatic Urethral Lift: A Novel Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

(2011) Henry H. Woo et al.   Journal of Sexual Medicine

Effects of 100 and 300 Units of Onabotulinum Toxin A on Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Phase II Randomized Clinical Trial

(2011) E. David Crawford et al.   JOURNAL OF UROLOGY

Prostatic Urethral Lift: Two-year Results After Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

(2011) Peter T. Chin et al.   UROLOGY

The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians

(2011) Neal Shore et al.   Therapeutic Advances in Chronic Disease

Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function

(2010) João Silva et al.   BJU INTERNATIONAL

Botulinum neurotoxin A for male lower urinary tract symptoms

(2010) Emmanuel Chartier-Kastler et al.   CURRENT OPINION IN UROLOGY

Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302 for the Targeted Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

(2010) Samuel R. Denmeade et al.   EUROPEAN UROLOGY

NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia

(2010) Neal Shore   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Progression of Lower Urinary Tract Symptoms in Older Men: A Community Based Study

(2010) J. Kellogg Parsons et al.   JOURNAL OF UROLOGY

Male Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH)

(2010) Claus G. Roehrborn   MEDICAL CLINICS OF NORTH AMERICA

Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport™

(2010) Mohammadreza Nikoobakht et al.   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY

Injectables in the prostate

(2009) Arash M Saemi et al.   CURRENT OPINION IN UROLOGY

Botulinum neurotoxin A for benign prostatic hyperplasia

(2009) Athanassios Oeconomou et al.   CURRENT OPINION IN UROLOGY

A Refocus on the Bladder as the Originator of Storage Lower Urinary Tract Symptoms: A Systematic Review of the Latest Literature

(2009) Alexander Roosen et al.   EUROPEAN UROLOGY

CHANGES IN SEXUAL FUNCTION IN MEN RANDOMIZED INTO A TWO-STAGE PHASE II TRIAL OF 100 AND 300 UNITS BOTULINUM NEUROTOXIN TYPE A (BONT-A) FOR THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)

(2009) Reginald Bruskewitz   JOURNAL OF UROLOGY

Prostate Volume Changes Over Time: Results From the Baltimore Longitudinal Study of Aging

(2009) Stacy Loeb et al.   JOURNAL OF UROLOGY

Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy

(2009) Hann-Chorng Kuo et al.   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY

Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment

(2009) João Silva et al.   BMC Urology

BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE

(2008) Claus G. Roehrborn   BJU INTERNATIONAL

Is Botulinum Neurotoxin Type A (BoNT-A) a Novel Therapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement? A Review of the Literature

(2008) Athanassios Oeconomou et al.   EUROPEAN UROLOGY

Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat

(2008) João Silva et al.   EUROPEAN UROLOGY

Urologic Diseases in America Project: Benign Prostatic Hyperplasia

(2008) John T. Wei et al.   JOURNAL OF UROLOGY

Relief by Botulinum Toxin of Lower Urinary Tract Symptoms Owing to Benign Prostatic Hyperplasia: Early and Long-Term Results

(2008) Giuseppe Brisinda et al.   UROLOGY

The Long-Term Relationship between a Real Change in Prostate Volume and a Significant Change in Lower Urinary Tract Symptom Severity in Population-Based Men: The Krimpen Study

(2007) J.L.H. Ruud Bosch et al.   EUROPEAN UROLOGY

Intraprostatic Botulinum Toxin Type A Injection in Patients Unfit for Surgery Presenting with Refractory Urinary Retention and Benign Prostatic Enlargement. Effect on Prostate Volume and Micturition Resumption

(2007) João Silva et al.   EUROPEAN UROLOGY

Botulinum Toxin A (Botox®) Intradetrusor Injections in Adults with Neurogenic Detrusor Overactivity/Neurogenic Overactive Bladder: A Systematic Literature Review

(2007) Gilles Karsenty et al.   EUROPEAN UROLOGY